Nov 3 (Reuters) - Young women who were vaccinated against human papillomavirus (HPV) in their teens with an older GlaxoSmithKline (GSK.L), opens new tab product called Cervarix had up to an 87% ...

GlaxoSmithKline's (GSK) cervical cancer vaccine, Cervarix, was today confirmed by the Netherlands Vaccine Institute (NVI) as the cervical cancer vaccine for the Dutch National Immunisation ...

beyond what had at first been anticipated," said Thomas Breuer, head of global clinical R&D at GSK Biologicals. Glaxo is waiting for approval in the U.S. market for Cervarix. U.S. approval was ...

LONDON (MarketWatch) -- Drug maker GlaxoSmithKline PLC GSK Monday said Cervarix, a cervical cancer vaccine expected to become a multibillion-dollar product, has been approved by health regulators ...

GSK has trumpeted head-to-head research showing Cervarix prompted a sharper immune response than Gardasil did. And it has touted data showing that Cervarix actually protects against five cancer ...

GSK) announced today that a two-dose schedule for its HPV vaccine Cervarix [Human Papillomavirus bivalent (types 16, 18) Vaccine, Recombinant)] has been approved by China's NMPA for girls aged 9 ...

Cervarix is a vaccine indicated for the prevention ... In a statement to FiercePharma, a spokesperson for GSK said, “With another HPV vaccine available in the U.S., patients will continue ...

That was after GSK had satisfied requests contained in a complete response letter issued in 2007 requesting more data. Cervarix can now compete against Merck & Co’s well-established jab Gardasil, ...

Glaxosmithkline (GSK) Cervarix cervical cancer product has received marketing approval from the European Commission for all EU countries. The vaccine, which prevents cancers related to human ...

GSK) successfully blocks the virus that causes most cases of cervical cancer, the Food and Drug Administration said Friday. In documents posted online, the FDA said Cervarix – vaccine against hu ...